SenzaGen granted its first patent for GARD potency biomarker test16 Jun 2019
Company can now offer an animal-free test method to quantify the strength of an allergenic effect.
SenzaGen's patent application to protect a biomarker signature that measures how strongly allergenic a substance is has now been granted in Europe. The patent is SenzaGen's first patent in the area of potency classification. The patent's validity extends to 2036.
The technology of SenzaGen's patent is implemented in the company's testing application, which for the first time makes it possible to measure the allergenicity of chemical substances, so-called potency classification, without animal research.
“Getting this patent approved for the European market is commercially interesting, as there is a ban within the EU on the sale of animal-tested cosmetic products. Furthermore, to quantify how strong the allergenic effect is according to CLP/GHS is a requirement in the EU chemical regulation REACH. As the only company in the world, SenzaGen can now offer an animal-free test method for this”, says Anki Malmborg Hager, CEO of SenzaGen.
SenzaGen’s IP strategy is to protect the company’s technology in all geographically important markets. Already granted in Europe, China and Hong Kong, patent applications for GARD skin are currently being processed by the patent authorities in countries where animal testing is prohibited or where a ban is expected to be introduced, including the US, Canada and India. In addition, the patent portfolio includes several ongoing patent applications for GARD potency and other GARD products.
SenzaGen’s GARD product portfolio consists of a set of allergy tests with industry-leading performance and accuracy. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence, and replace animal experiments for the cosmetics, chemical and pharmaceutical industries for their tests on whether chemical substances in products can be allergenic.
Colorcon launches new $50 million VC Fund
17 Sep 2019
The fund will target investments in transformational solutions across manufacturing, supply chain, and delivery of pharmaceutical products and services.Read more
M2i Life Sciences completes a historic fundraising of 60 million Euros
16 Sep 2019
To support its strong growth, M2i Life Sciences has concluded a capital increase of 60 million Euros with five leading investors (ADM Capital, Eurazeo Growth, Téthys Invest, Creadev and France 2i fund managed by RAISE Impact).Read more
Daiichi Sankyo releases new generic formulation for sustained cancer pain treatment
13 Sep 2019
New formulation of oxycodone hydrochloride contains the narcotic antagonist naloxone in order to prevent abuse.Read more
Mallinckrodt to sell BioVectra for $250 million
11 Sep 2019
Transaction continues to advance Mallinckrodt's strategic focus on branded, high-growth biopharmaceuticals by monetizing a non-core business.Read more
Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic
10 Sep 2019
Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.Read more
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development
10 Sep 2019
Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.Read more
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market
9 Sep 2019
Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.Read more
Catalent to open new clinical supply facility in San Diego
6 Sep 2019
Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.Read more
Take part in pharma’s largest reputation survey
6 Sep 2019
Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.Read more
BioCity backs world's first Rx to OTC switch incubator
5 Sep 2019
Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation